<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828165</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-300-101</org_study_id>
    <nct_id>NCT00828165</nct_id>
  </id_info>
  <brief_title>A Safety Study of ARRY-300 in Healthy Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Array Biopharma, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Array BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 study, involving a 1-day dosing period (up to 3 dosing periods per&#xD;
      subject), designed to test the safety of investigational study drug ARRY-300 in healthy&#xD;
      subjects. Approximately 12 healthy subjects from the US will be enrolled in this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests, vital signs and electrocardiograms.</measure>
    <time_frame>Duration of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the pharmacokinetics (PK) of the study drug and metabolites in terms of plasma concentrations.</measure>
    <time_frame>Following a single dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the pharmacodynamic (PD) activity of the study drug on biomarkers.</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ARRY-300</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARRY-300, MEK inhibitor; oral</intervention_name>
    <description>single dose, escalating</description>
    <arm_group_label>ARRY-300</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female (females must be of non-childbearing potential) between the&#xD;
             ages of 18 and 50 years, inclusive.&#xD;
&#xD;
          -  Body mass index (BMI) of 18 kg/m2 to 35 kg/m2; and a total body weight &gt; 50 kg (110&#xD;
             lbs) and &lt; 113 kg (280 lbs).&#xD;
&#xD;
          -  Additional criteria exist.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Evidence or history of clinically significant hematologic, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic,&#xD;
             dermatologic, or allergic disease (including drug allergies that are clinically&#xD;
             significant and not remote, but excluding untreated, asymptomatic, seasonal allergies&#xD;
             at the time of dosing).&#xD;
&#xD;
          -  A condition possibly affecting drug absorption (e.g., gastrectomy).&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding.&#xD;
&#xD;
          -  A positive test for drugs or alcohol.&#xD;
&#xD;
          -  Use of tobacco- or nicotine-containing products in excess of 5 cigarettes per day, or&#xD;
             daily use of pipe, cigar, chewing tobacco or nicotine gum or patches.&#xD;
&#xD;
          -  Treatment with an investigational drug within 30 days prior to first dose of study&#xD;
             drug.&#xD;
&#xD;
          -  Use of prescription or nonprescription drugs, vitamins, grapefruit juice, and dietary&#xD;
             or herbal supplements within 14 days prior to the first dose of study drug. As&#xD;
             exceptions, acetaminophen may be used at doses of ≤ 1 g/day or ibuprofen may be used&#xD;
             at doses of ≤ 800 mg/day until 24 hours prior to first dose of study drug.&#xD;
&#xD;
          -  Blood donation of ≥ 1 pint within 30 days prior to first dose of study drug.&#xD;
&#xD;
          -  Evidence of hepatitis B or C, or human immunodeficiency virus (HIV) infection upon&#xD;
             serological testing.&#xD;
&#xD;
          -  Additional criteria exist.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Development, LP</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 22, 2009</study_first_submitted>
  <study_first_submitted_qc>January 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2009</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

